| Fasiglifam, a potent, selective G protein-coupled receptor 40 agonist, is primarily cleared by the liver. |
| Hepatic impairment does not impact pharmacokinetics of a single, 25-mg dose of fasiglifam, suggesting no dose reduction is needed. |
| A single, 25-mg dose of fasiglifam was well tolerated with no reports of hypoglycemia. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.